{
    "pmcid": "8139655",
    "qa_pairs": {
        "How were the alpaca-derived nanobodies engineered to enhance their binding affinities?": [
            "By creating homo-bivalent and hetero-bivalent formats",
            "By conjugating them with gold nanoparticles",
            "By incorporating them into liposomal formulations",
            "By attaching them to polyethylene glycol (PEG) chains"
        ],
        "What is one of the potential applications of the high-affinity nanobodies according to the study?": [
            "Development into therapeutics and diagnostic tools for COVID-19",
            "Use as a vaccine adjuvant to enhance immune response",
            "Incorporation into antiviral coatings for surfaces",
            "Application in gene therapy to deliver antiviral genes"
        ],
        "What is the primary target of the alpaca-derived nanobodies discussed in the study?": [
            "The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2",
            "The envelope protein of SARS-CoV-2"
        ],
        "What was the range of KD values for the initial nanobodies identified in the study?": [
            "2.6 to 113 nM",
            "0.5 to 50 nM",
            "10 to 200 nM",
            "1.0 to 150 nM"
        ],
        "Which mutation in the RBD did the nanobodies maintain binding to, indicating potential cross-reactivity?": [
            "N501Y mutation",
            "D614G mutation",
            "E484K mutation",
            "K417N mutation"
        ]
    }
}